Background

The real-world application of STRIDE-II treatment targets to identify whether disease control is optimal in Crohn’s disease (CD) and ulcerative colitis (UC) is not well known.

Aims

This study aimed to estimate proportions of patients with suboptimally controlled CD and UC in real-world Canadian healthcare settings and the impact on quality of life (QoL).

Methods

The noninterventional, multicenter, observational IBD-PODCAST Canada study comprised a single study visit involving routine assessments, patient- and clinician-completed questionnaires, and a retrospective chart review. Primary outcomes were proportions of patients with STRIDE-II-based red flags indicative of suboptimal disease control and mean ± standard deviation Short Inflammatory Bowel Disease Questionnaire (SIBDQ) scores. Secondary outcomes included proportions of patients and clinicians subjectively reporting suboptimal control.

Results

Among 163 enrolled patients from 10 sites, 45/87 patients with CD (51.7%; 95% CI: 40.8%, 62.6%) and 33/76 patients with UC (43.3%; 95% CI: 32.1%, 55.3%) had suboptimal disease control based on STRIDE-II criteria. Suboptimal control was subjectively reported at lower proportions (patients: CD, 15.0%; UC, 18.6%; clinicians: CD, 19.5%; UC, 25.0%). Numerically lower SIBDQ scores were observed with suboptimal control (CD, 43.0 ± 10.8; UC, 42.5 ± 12.0) than with optimal control (CD, 58.2 ± 7.2; UC, 57.8 ± 6.6).

Conclusions

Approximately 50% (CD) and 40% (UC) of patients from real-world Canadian practices had suboptimal disease control based on STRIDE-II criteria. Suboptimal control was underestimated by patients and clinicians and accompanied by reduced QoL, suggesting further efforts to implement STRIDE-II treat-to-target strategies are needed.

中文翻译：

---

次优疾病控制对患者生活质量的影响：来自 IBD-PODCAST 加拿大观察试验的真实世界数据

背景

STRIDE-II 治疗目标在实际应用中确定克罗恩病 (CD) 和溃疡性结肠炎 (UC) 疾病控制是否最佳的情况尚不清楚。

目标

本研究旨在估计加拿大现实医疗保健环境中 CD 和 UC 控制不佳的患者比例及其对生活质量 (QoL) 的影响。

方法

这项非介入性、多中心、观察性 IBD-PODCAST 加拿大研究包括一次研究访问，涉及常规评估、患者和临床医生填写的问卷以及回顾性图表审查。主要结局是基于 STRIDE-II 的危险信号（表明疾病控制不佳）的患者比例以及简短炎症性肠病问卷 (SIBDQ) 评分的平均值±标准差。次要结果包括主观报告控制不佳的患者和临床医生的比例。

结果

在来自 10 个中心的 163 名入组患者中，45/87 名 CD 患者（51.7%；95% CI：40.8%、62.6%）和 33/76 名 UC 患者（43.3%；95% CI：32.1%、55.3%）患有基于 STRIDE-II 标准的次优疾病控制。主观报告的次优控制比例较低（患者：CD，15.0%；UC，18.6%；临床医生：CD，19.5%；UC，25.0%）。次优对照（CD，43.0 ± 10.8；UC，42.5 ± 12.0）的 SIBDQ 评分在数值上低于最佳对照（CD，58.2 ± 7.2；UC，57.8 ± 6.6）。

结论

根据 STRIDE-II 标准，加拿大实际实践中大约 50% (CD) 和 40% (UC) 的患者疾病控制不佳。患者和临床医生低估了次优控制，并伴有生活质量下降，表明需要进一步努力实施 STRIDE-II 治疗目标策略。